Mesoporous Silica Nanoparticles: Drug Delivery Vehicles for Antidiabetic Molecules

Abstract

Mesoporous silica nanoparticles (MSNs) are promising nanomaterials that are widely used in biomedical applications like drug delivery, diagnosis, bio-sensing and cell tracking. MSNs have been investigated meticulously in the drug-delivery field due to their unique chemical and pharmacokinetic properties, such as highly ordered mesopores, high surface area and pore volume, tuneable pore size, stability, surface functionalisation, and biocompatibility. MSN-based nanocomposites have been used to deliver therapeutic molecules like insulin, GLP-1, exenatide, DPP-4 inhibitor and plasmid-containing GLP-1 genes for managing diabetes mellitus for the last decade. The functionalisation properties of MSNs make them substantially capable of the co-delivery, controlled delivery and stimuliresponsive delivery of antidiabetic drugs. This review focuses on the delivery of antidiabetic therapeutics with special emphasis on the functionalisation of MSNs and stimuliresponsive delivery.

Exploring mesoporous silica nanoparticles as oral insulin carriers: In-silico and in vivo evaluation

“…An efficient and non-toxic oral insulin delivery system could revolutionize the management of type 1 diabetes for patients, providing them with greater ease and comfort in controlling their blood glucose levels compared to traditional methods [ 31 , 32 ]. This study aimed to achieve two goals.…”

Development of Ac2-26 Mesoporous Microparticle System as a Potential Therapeutic Agent for Inflammatory Bowel Diseases

“…Together, these properties allow the safe transport of small molecules through the TGI. [51][52][53][54][55][56] In fact, by modeling the SAXS data, in combination with the NAI results, it was possible to conclude that a fraction of the Ac2-26 peptide was loaded into the SBA-15 mesopores. In contrast, the remaining amount is on the silica surface, a similar scenario observed in previous studies, 44,57 in which the authors loaded proteins instead of peptides.…”

Multifunctional nanoparticle-mediated combining therapy for human diseases

“…Various NPs were reported for delivering therapeutic compounds, including insulin, dipeptidyl peptidase-4 (DPP4) inhibitors, and plasmids containing the GLP-1 gene. 418 To relieve the enzymatic breakdown of certain antidiabetic drugs like insulin in the gastrointestinal (GI) tract, the scientists designed several NPs, including mesoporous silica NPs (MSNs), liposomes, gold NPs and polymer NPs. However, drug codelivery systems may be exploited to simplify treatment regimens and improve patient compliance.…”